of patients (6, 12, 24, 36 months). Monotherapy and combined therapy with more antiepileptics was evaluated. The cohort included 55 patients more or less with partial seizures from refracter epilepsy group. Two patients (3.6 %) were excluded for side effects of the therapy. The cohort included 27 men and 28 women with the mean age of 34.29 ± 15.23 years. Average dose of Levetiracetam was 2000 ± 1000 mg. Not attack condition was recorded in 23.9 % of patients with added therapy and in 77.8 % of patients with monotherapy. Disappearing of specific epileptic activity in EEG recording was found in 43.6 % of patients. Levetiracetam was found to be new effective antiepileptics useful also for refracter epilepsies in monotherapy and added therapy as well. Reduction of seizures was observed also during long-term administration and regulation in EEG finding is also possible. Side effects of the therapy are rare.